The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tsarenko S.V.

Lechebno-reabilitatsionnyĭ tsentr Minzdrava RF

Dzyadz’ko A.M.

Republican Scientific and Practical Center of Organ and Tissue Transplantation, Minsk, Republic of Belarus

Rybalko S.S.

Republican Scientific and Practical Center of Neurology and Neurosurgery, Minsk, Republic of Belarus

Glibenclamide as a promising agent for prevention and treatment of cerebral edema

Authors:

Tsarenko S.V., Dzyadz’ko A.M., Rybalko S.S.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2017;81(3): 88‑93

DOI: 10.17116/neiro201781388-93

Views: 5369

Downloaded: 103

Download PDF (RU)
Download PDF
Contact the author
Table of contents

GLIBENCLAMIDE AS A PROMISING AGENT FOR PREVENTION AND TREATMENT OF CEREBRAL EDEMA
GLIBENCLAMIDE AS A PROMISING AGENT FOR PREVENTION AND TREATMENT OF CEREBRAL EDEMA

To cite this article:

Tsarenko SV, Dzyadz’ko AM, Rybalko SS. Glibenclamide as a promising agent for prevention and treatment of cerebral edema. Burdenko's Journal of Neurosurgery. 2017;81(3):88‑93. (In Russ., In Engl.)
https://doi.org/10.17116/neiro201781388-93

Подписка 2025-2 (Burdenko's Journal of Neurosurgery)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Possibilities of physiotherapy in glaucomatous optic neuropathy after glaucoma surgery. Russian Annals of Ophthalmology. 2024;(3):88-94
Pharmacological effe­cts of fonturacetam (Actitropil) and prospects for its clinical use. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):21-31
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
Neuroprotective therapy for age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):152-158
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Neurocytoprotection adva­nces in repe­rfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88
Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

The article presents a review of the literature on the use of a fundamentally new technique for prevention and treatment of cerebral edema. A drug glibenclamide, which is used to treat type 2 diabetes mellitus, is able to reduce cerebral edema and neuronal damage as evidenced by the results of preclinical trials in rodents and the first results of drug application in patients. The article describes the mechanism of glibenclamide action and discusses the potential for its application.

Keywords:

malignant cerebral edema
neuroprotection
sulfonylurea receptor 1 (SUR-1)
glibenclamide

Authors:

Tsarenko S.V.

Lechebno-reabilitatsionnyĭ tsentr Minzdrava RF

Dzyadz’ko A.M.

Republican Scientific and Practical Center of Organ and Tissue Transplantation, Minsk, Republic of Belarus

Rybalko S.S.

Republican Scientific and Practical Center of Neurology and Neurosurgery, Minsk, Republic of Belarus

List of references:

  1. Caffes N, Kurland D, Gerzanich V, Simard J. Glibenclamide for the Treatment of Ischemic and Hemorrhagic Stroke. IJMS. 2015;16(3):4973-4984. doi:10.3390/ijms16034973
  2. Simard J, Woo S, Schwartzbauer G, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. Journal of Cerebral Blood Flow & Metabolism. 2012;32(9):1699-1717. doi:10.1038/jcbfm.2012.91
  3. Mehta R, Tosun C, Ivanova S, Tsymbalyuk N, Famakin B, Kwon M, Castellani R, Gerzanich V, Simard J. Sur1-Trpm4 Cation Channel Expression in Human Cerebral Infarcts. J Neuropathol Exp Neurol. 2015;74(8):835-849. doi:10.1097/NEN.0000000000000223
  4. Kunte H, Schmidt S, Eliasziw M, del Zoppo G, Simard J, Masuhr F, Weih M, Dirnagl U. Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke. Stroke. 2007;38(9):2526-2530. doi:10.1161/strokeaha.107.482216
  5. Simard J, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke Supplemental Methods. Stroke. 2008;40(2):604-609. doi:10.1161/strokeaha.108.522409
  6. Simard J, Chen M, Tarasov K, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West G, Gerzanich V. Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke. Nature Medicine. 2006;12(4):433-440. doi:10.1038/nm1390
  7. Simard J, Woo S, Tsymbalyuk N, Voloshyn O, Yurovsky V, Ivanova S, Lee R, Gerzanich V. Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke. Transl Stroke Res. 2012;3(2):286-295. doi:10.1007/s12975-012-0149-x
  8. Simard J, Kilbourne M, Tsymbalyuk O, Tosun C, Caridi J, Ivanova S, Keledjian K, Bochicchio G, Gerzanich V. Key Role of Sulfonylurea Receptor 1 in Progressive Secondary Hemorrhage after Brain Contusion. Journal of Neurotrauma. 2009;26(12):2257-2267. doi:10.1089/neu.2009.1021
  9. Simard J, Tsymbalyuk N, Tsymbalyuk O, Ivanova S, Yurovsky V, Gerzanich V. Glibenclamide Is Superior to Decompressive Craniectomy in a Rat Model of Malignant Stroke Online-Only Data Supplement (Methods). Stroke. 2010;41(3):531-537. doi:10.1161/strokeaha.109.572644
  10. Sheth K, Kimberly W, Elm J, Kent T, Mandava P, Yoo A, Thomalla G, Campbell B, Donnan G, Davis S, Albers G, Jacobson S, Simard J, Stern B. Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke. Stroke. 2013;45(1):281-283. doi:10.1161/strokeaha.113.003352
  11. Sheth K, Taylor KW, Elm J, Kent T, Yoo A, Thomalla G, Campbell B, Donnan G, Davis S, Albers G, Jacobson S, del Zoppo G, Marc Simard J, Stern B, Mandava P. Exploratory Analysis of Glyburide as a Novel Therapy for Preventing Brain Swelling. Neurocritical Care. 2014;21(1):43-51. doi:10.1007/s12028-014-9970-2
  12. Sheth K, Elm J, Beslow L, Sze G, Kimberly W. Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocritical Care. 2015;24(1):132-139. doi:10.1007/s12028-015-0189-7
  13. GAMES-RP: Can Glyburide Reduce Edema in Severe Stroke? Medscape. Feb 24, 2016. International Stroke Conference (ISC) 2016. Abstracts LB6 and LB24. Presented February 19, 2016.
  14. Pallan TV, Ahmed I. Glyburide in Treating Malignant Cerebral Edema. Blocking Sulfonyl Urea One Receptors. J of Vascular and Interventional Neurology. 2014 Nov;14:22-24. doi:10.1212/wnl.78.1_meetingabstracts.p06.239
  15. Jayakumar A, Valdes V, Tong X, Shamaladevi N, Gonzalez W, Norenberg M. Sulfonylurea Receptor 1 Contributes to the Astrocyte Swelling and Brain Edema in Acute Liver Failure. Transl Stroke Res. 2014;5(1):28-37. doi:10.1007/s12975-014-0328-z
  16. Shimizu S, Oikawa R, Tsounapi P, Inoue K, Shimizu T, Tanaka K, Martin D, Honda M, Sejima T, Tomita S, Saito M. Blocking of the ATP sensitive potassium channel ameliorates the ischaemia-reperfusion injury in the rat testis. Andrology. 2014;2(3):458-465. doi:10.1111/j.2047-2927.2014.00199.x
  17. Pan'kiv VI. Mesto glibenklamida v dialektike sovremennoi sakharosnizhayushchei terapii s pozitsii bezopasnosti i kardioprotektsii. Mіzhnarodnii endokrinologіchnii zhurnal. 2013;2:55-61. (In Russ.). Available at: http://nbuv.gov.ua/UJRN/Mezh_2013_2_12. Accessed August 21, 2016
  18. Van Basten JP, van Hoek B, Zeijen R, Stockbrügger R. Glyburide-induced Cholestatic Hepatitis and Liver Failure. Case-report and Review of the Literature. Neth J Med. 1992 Jun;40(5-6):305-307.
  19. Grover G. Protective Effects of ATP-Sensitive Potassium-Channel Openers in Experimental Myocardial Ischemia. Journal of Cardiovascular Pharmacology. 1994;24:S18-S27. doi:10.1097/00005344-199424004-00004
  20. Korpachev VV, Korpacheva-Zinych LV. Glibenklamid i smertnost' ot serdechno-sosudistykh zabolevanii. Mіzhnarodnii endokrinologіchnii zhurnal. 2009;4 (22). (In Russ.). Available at: http://www.mif-ua.com/archive/article/9491

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.